Pfs25 malaria vaccine - MVI

Drug Profile

Pfs25 malaria vaccine - MVI

Alternative Names: Malaria transmission-blocking Pfs25-Pfs25 conjugate vaccine; Pfs25 antigen; Pfs25 EPA; Pfs25 Pfs25; Pfs25 VLP; Pfs25 VLP-FhCMB; Pfs25-EPA/Alhydrogel; Transmission-blocking malaria vaccine - iBio/Fraunhofer

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins Bloomberg School of Public Health; Malaria Vaccine Initiative; Sabin Vaccine Institute
  • Developer Fraunhofer USA Center for Molecular Biotechnology; National Institute of Allergy and Infectious Diseases
  • Class Antimalarials; Parasitic vaccines; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Malaria

Most Recent Events

  • 20 Dec 2016 National Institute of Allergy and Infectious Diseases (NIAID) completes a phase I trial in Malaria (Prevention) in Mali (NCT01867463)
  • 18 Nov 2014 PATH MVI and Mymetics agree to co-develop a malaria vaccine candidate
  • 09 Oct 2014 Malaria Vaccine Initiative in-licenses Expression Technology® technology from Pfenex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top